Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia.
Publication/Presentation Date
1-1-2020
Abstract
While cytokine storm develops in a minority of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, novel treatment approaches are desperately needed for those in whom it does. Tocilizumab, an interleukin-6 receptor antibody, has been utilized for the treatment of cytokine storm in a number of severe inflammatory conditions, including in patients with severe coronavirus disease 2019 (COVID-19). Here, we present the first published case utilizing this therapy in a patient with underlying immunodeficiency. Our patient with aplastic anemia developed cytokine storm due to COVID-19 manifested by fever, severe hypoxia, pulmonary infiltrates, and elevated inflammatory markers. Following treatment with tocilizumab, cytokine storm resolved, and the patient was ultimately safely discharged from the hospital.
Volume
10
First Page
562625
Last Page
562625
ISSN
2234-943X
Published In/Presented At
Keiffer, G., French, Z., Wilde, L., Filicko-O'Hara, J., Gergis, U., & Binder, A. F. (2020). Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia. Frontiers in oncology, 10, 562625. https://doi.org/10.3389/fonc.2020.562625
Disciplines
Medicine and Health Sciences
PubMedID
33072589
Department(s)
Department of Medicine, Lehigh Valley Topper Cancer Institute
Document Type
Article